Aurora, Colo.—Nearly two-thirds of managed care stakeholders polled in a recent survey said they are covering some biosimilar products, with most of them reporting “meaningful” cost savings from the formulary strategy.
That level of acceptance and savings comes at a time when the market for biosimilars is on the upswing. Indeed, after years of slow market release, “there are now 31 biosimilar products that have been FDA approved, with 20 launches in a